NXGL, US65344E1073

NEXGEL stock fell 2.52 percent as strategic review advanced

Published on 10/04/2026 at 21:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NEXGEL stock traded at USD 0.17 on October 2, 2026, with market capitalization of USD 1.5 million. Q2 revenue reached USD 3.69 million.

NXGL, US65344E1073, Illustration mit AI erstellt.
NXGL, US65344E1073, Illustration mit AI erstellt.

NEXGEL stock (ISIN US65344E1073) was last at USD 0.17 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, down 2.52 percent on the session. The central corporate development is a strategic review and proposed platform reorganization introduced on September 24, 2026, according to the SEC.

Strategic review sets the direction

The filing says NEXGEL began using a shareholder update presentation titled Strategic Review & Proposed Platform Reorganization on September 24, 2026. The presentation was furnished under Regulation FD and outlines a review of operations, assets, liquidity and longer-term strategic direction.

The corporate move follows a shareholder vote on September 23, 2026. According to Stock Titan, investors approved an increase in authorized common shares from 25 million to up to 150 million and authorized a discretionary reverse split between 1-for-2 and 1-for-20.

Revenue growth meets a heavy loss

NEXGEL reported USD 3.69 million of revenue for the quarter ended June 30, 2026, compared with USD 2.88 million in the year-earlier quarter. The same report showed a GAAP net loss of USD 3.64 million, versus a GAAP net loss of USD 665,000 a year earlier, according to Markets Insider.

The latest quarterly figures therefore show a clear split between sales expansion and bottom-line pressure. The strategic review matters because the company is evaluating its asset portfolio and liquidity while the business absorbs its broader platform ambitions.

One analyst keeps a Hold view

Maxim Group analyst Naz Rahman maintained a Hold rating on September 25, 2026, as reported by Markets Insider. Investing.com lists a Neutral consensus based on one analyst, with zero Buy ratings, zero Sell ratings and one Hold rating, according to Investing.com.

For investors, the key tension is visible in the numbers: quarterly revenue reached USD 3.69 million, while the GAAP loss reached USD 3.64 million. The authorized-share decision and reverse-split authority also give the board additional capital-structure options during the review period.

NXGL remains near its yearly low

On October 2, 2026, NXGL traded at USD 0.17 on Nasdaq, with a 52-week range of USD 0.16 to USD 2.89. The session volume was 222,912 shares and market capitalization was USD 1.5 million as of the same date.

NEXGEL stock at a glance

  • Company: NEXGEL, Inc.
  • ISIN: US65344E1073
  • Ticker: NXGL
  • Trading venue: Nasdaq Capital Market
  • Price as of October 2, 2026, 4:00 p.m. ET: USD 0.17
  • Market capitalization: USD 1.5 million (as of October 2, 2026)
  • 52-week range: USD 0.16-2.89 (as of October 2, 2026)
  • Sector / Industry: Healthcare / Medical Instruments and Supplies

More news and analysis on NEXGEL stock

Disclaimer...

en | US65344E1073 | NXGL | boerse | 70228061 | bgmi